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DOT = diffuse optical tomography; DPDW = diffuse photon density wave; ICG = indocyanine green; MRI = magnetic resonance imaging; NIR =
near infrared.
Available online http://breast-cancer-research.com/content/3/1/041
Introduction
Tissue visualization with light is probably the most common
imaging practice in medicine and medical research. Histori-
cally, visual inspection of a patient or observation of tissues
using optical microscopes has been widely used to assess
structure and function. Those two examples use the human
retina as the recording medium. Generally, medical optical
imaging encompasses a large set of imaging technologies
that use light from the ultraviolet to the infrared region to
image tissue optical characteristics. Light offers wave-
length-dependent interactions with tissue that yield unique
contrast mechanisms for imaging; scattering, absorption,
and fluorescence of intrinsic and extrinsic tissue elements
reveal information on structure, physiology, biochemistry,
and molecular function.
Because of the important information that light reveals,
optical imaging has found many applications for in vivo
tissue measurements. Optical imaging has been used to
probe surface structures, such as the functional activation
of the exposed brain regions [1], skin cancers [2,3], and
those revealed by endoscopic procedures [3,4], but it has
also been used to investigate noninvasively the internal
function of large organs such as the breast [5–7] and the
unexposed brain [8,9]. There are, however, fundamental
differences between optical imaging of surface structures
and of large organs. Optical imaging, a high-resolution
technique for surface imaging, becomes an imaging
method with millimeter-scale resolution when probing
large organs. This is because tissue scatters light signifi-
cantly. Hence, photons that propagate inside tissue do not
follow straight paths as do X-ray photons, but rather they
diffuse and follow random paths [10••]. This process
impairs resolution. Tissue absorption may also be a com-
plication in imaging large tissues, depending on the wave-
length used and the target organ. For this reason the near
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infrared (NIR) part of the spectrum is typically selected for
imaging large organs because tissue exhibits low absorp-
tion in the NIR and allows light of safe power to penetrate
to depths of several centimeters.
Optical imaging may have a major role in breast cancer
research and detection, despite its low resolution, by
assessing functional and molecular cancer characteristics.
Intrinsically, the main light absorbers of the breast in the
NIR window are oxyhemoglobin and deoxyhemoglobin.
Hence, the optical technique is a unique noninvasive tech-
nology for imaging and quantifying vascularization, and
especially oxygen saturation of breast tumors. These fea-
tures are associated with angiogenesis and hypoxia,
which are two correlates of breast malignancy. Further-
more, there is an intensified effort to produce extrinsic
absorbing and fluorescent probes, especially for the NIR
region, that target physiologic and genetic responses
[11–13]. These probes could increase cancer contrast
and target specific gene expression that could eventually
improve early detection limits and specificity, but also help
in the design of optimum treatments and in assessing
treatment efficacy.
The unique features of the optical method, along with its
high sensitivity for detecting photons and use of nonioniz-
ing radiation, renders optical imaging a technology that
could complement existing breast imaging techniques for
cancer detection and characterization. The compatibility of
the technology with most other radiologic imaging tech-
niques allows the creation of combined modalities for
simultaneous breast examinations that yield a superior
feature set. Furthermore, optical methods are economic
and can acquire data continuously; hence, they may be
used for real-time monitoring.
In the following commentary, a brief historical perspective
on breast cancer optical imaging is presented and current
advances in this field are discussed. Specific focus is
given to the infant clinical steps of DOT, a method that
uses light and that can image and quantify tissue optical
properties (and thus function) in three dimensions. The
combination of the technique with novel vascular and mol-
ecular contrast agents is also discussed, and the possibil-
ity of coupling the optical method with other medical
modalities for improving the information content of the
composite examination is outlined.
Transillumination
Breast cancer detection using optical imaging is not a
novel idea; it dates back to 1929 when Cutler [14] shined
light through the pendant breast to observe the absorption
pattern on the other side. This method was termed ‘trans-
illumination’ or ‘diaphanography’. Although cancerous
lesions with increased vascularization were detected,
certain other benign formations with increased hemoglobin
content also yielded absorption contrast. Because no
absorption quantification or high-resolution architectural
information was available, the method did not offer suffi-
cient specificity for clinical utility. Technologic break-
throughs during the late 1970s and in the 1980s,
specifically the use of video cameras in the visible or NIR
parts of the spectrum, revived interest in transillumination.
However, the basic limitations that Cutler encountered,
regarding differentiating between malignant and benign
lesions, were not significantly improved by the use of better
recording media. Furthermore, reports on the sensitivity of
the method varied significantly. Sensitivity values as high as
96% have been reported [15,16], but several studies
[5,17,18] found transillumination to yield sensitivity around
60% and to be significantly inferior to X-ray mammography.
Transillumination was revisited during the 1990s, employ-
ing further advances in source and detection technology.
Laser light and photon pulses in the picosecond or femp-
tosecond range have been employed in breast imaging
[19]. This technique allows the formation of images using
photons that arrive at the detector at selected time
windows relative to the time at which the incident photon
pulse was injected into the medium. In this manner,
photons that have undergone minimum scattering and
therefore arrive earlier at the detector can be selected to
produce higher resolution images, but this method usually
operates at low signal : noise ratio. Other time windows
have also been investigated [19]. Additionally, laser light
of modulated intensity has been used [6] to correct for
light attenuation variations seen on the projected images
(‘shadowgrams’) caused by breast thickness variations. A
craniocaudal and oblique view that was obtained at
690 nm from a 72-year-old patient with an invasive ductal
carcinoma using this method is shown in Fig. 1 [20]. The
carcinoma was 2.5 cm in diameter and appears in both
views with high contrast, probably because of increased
hemoglobin content. Patterns of surface vessels are also
apparent on the images.
Sensitivity and specificity measures using these
advanced transillumination approaches have not yet
appeared in the literature. Probably the most promising
characteristics of these approaches, however, are the fol-
lowing: the use of multiple distinct wavelengths that
could enhance sensitivity and specificity on the basis of
spectral signatures; and the use of a set of assumptions
combined with theoretic models that could provide a
quantified estimation of the geometric and optical para-
meters of the lesion measured [19,21].
Diffuse optical tomography
A breakthrough in optical imaging that was made during
the past decade is the development of DOT, a tech-
nique that employs diffuse light that propagates through
tissue, at multiple projections, to yield three-dimensionalc
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quantified tomographic images of the internal optical
properties of organs. The technique employs technologic
and mathematical advances and, depending on the tech-
nology employed, can yield quantified, three-dimensional
maps of absorption, scattering, vascularization, oxygena-
tion, and contrast agent uptake in either fluorescence or
absorption mode.
In comparison with transillumination, the technique offers
superior quantification accuracy, independent determina-
tion of absorption, scattering and fluorescence lifetime
and yield, three-dimensional imaging capability, and lesion
size determination because of the multiple-projection infor-
mation content and inclusive theoretic approaches it uses.
Generally, DOT uses a theoretic model (typically a
numeric or analytic solution of the diffusion equation
[22••]) to describe the propagation of photons into diffuse
media and to predict the measurements of the experimen-
tal arrangement (forward problem). Then, inversion
methods, which are based on this forward model, recon-
struct the optical properties of the breast under investiga-
tion by operating on a set of light measurements that are
taken through this tissue. If the method employs measure-
ments at multiple distinct wavelengths, spectral informa-
tion can also be obtained.
Although constant intensity light can be used for DOT,
especially when only changes in tissue absorption or fluo-
rescence are to be imaged, there are certain advantages
with the use of short photon pulses (in the picosecond
range or less) or light of modulated intensity. DOT
employs the information gained by advanced photon tech-
nology in a more comprehensive and meaningful way than
does transillumination. Photon pulses or light of modulated
intensity direct photon waves into diffuse media (called
diffuse photon density waves or [DPDWs] [23]). The use
of DPDWs in the megahertz range can separate, and inde-
pendently image and quantify the distribution of tissue
absorption and scattering properties [23]. In fluorescence
mode, the use of DPDW can be used to image fluo-
rophore concentration and lifetime in three dimensions.
The use of photon pulses is equivalent (via Fourier trans-
formation) to measurements with light that is modulated at
multiple frequencies (practically up to 1 GHz). The use of
multiple frequencies can be simultaneously combined in
one reconstruction scheme to increase the information
content and the accuracy of the inversion [24].
DOT has recently been applied to clinical imaging of the
breast, and several prototype breast optical tomographic
systems have been developed that operate using photon
pulses [24], light of modulated intensity [25] or light of
constant intensity [26]. Our group has demonstrated
quantified DOT images of uptake of the NIR contrast
agent indocyanine green (ICG) from breast lesions in a
study that was performed simultaneously with gadolinium-
enhanced magnetic resonance imaging (MRI) for valida-
tion [7]. Fig. 2 shows a result obtained from a 70-year-old
patient with a 0.8 cm infiltrating ductal carcinoma. Fig. 2a
shows a sagittal magnetic resonance image after gadolin-
ium contrast enhancement (shown in color) passing
through the center of the cancerous lesion. Fig. 2b depicts
a coronal DOT image of the absorption coefficient
increase due to ICG administration. This image is perpen-
dicular to the plane in Fig. 2a, and was obtained at
830 nm for the volume of interest indicated on Fig. 2a with
the dashed line box. Fig. 2c shows a magnetic resonance
coronal reslicing of the volume of interest with the same
dimensions as Fig. 2b. Furthermore tomographic images
of intrinsic contrast have been also demonstrated [27].
Figure 3 displays quantified coronal images of the absorp-
tion and reduced scattering coefficients obtained from the
breast of a patient with a well-localized 3.4-cm fibroade-
noma in the upper central region of her breast at 754 nm.
Optical imaging of intrinsic and extrinsic
breast cancer activity
Imaging of intrinsic contrast
The capacity of optical imaging, and especially DOT, to
image and quantify intrinsic and extrinsic tissue optical
properties is discussed above. Intrinsic optical contrast
offers significant functional information. Imaging of scatter-
ing may be associated with structural characteristics and
the concentrations of organelles. More importantly,
imaging of the absorption coefficient at appropriately
selected wavelengths can quantify the concentrations of
water and oxyhemoglobin and deoxyhemoglobin of breast
tumors, and obtain measures of hemoglobin concentration
Available online http://breast-cancer-research.com/content/3/1/046
Figure 1
Breast transillumination. Craniocaudal (cc) and oblique (ob) views of
the left (L) breast of a 72-year-old patient affected by invasive ductal
carcinoma. The cancer diameter is 2.5 cm. The cancer appears with
high contrast in both views of the breast. From Fantini et al [20], with
permission from the Optical Society of America.and hypoxia. Therefore, the optical method is unique in
assessing and quantifying those important functional
tissue and cancer characteristics. Correlation of intrinsic
signals and malignancy has been demonstrated [28••].
The detection limits and the diagnostic capacity of any
combination of the intrinsic features on a screening popu-
lation remain to be seen, because the limited number of
patients examined by DOT thus far does not allow such
factors to be identified.
Imaging of contrast agents
Similar to other clinical imaging modalities, a novel
element that can enhance the potential applications of
optical imaging is the use of contrast agents. In the NIR
range the most widely used contrast agent is ICG,
because it is a safe, US Food and Drug Administration-
approved NIR absorbing and fluorescing dye. ICG is an
intravascular contrast agent that may extravasate through
vessels of high permeability, such as cancerous vessels.
Therefore, ICG imaging of the breast mainly probes per-
meability and vascularization [7]. Other ICG derivatives
with extravascular distribution mechanisms have recently
been considered [11] for diagnostic purposes. Several
other imaging methods can target such features with the
use of appropriate contrast agents. Similar to nuclear
imaging, however, the optical method generally can detect
very small concentrations of chromophores or fluoro-
phores, but without using ionizing radiation and at a
reduced cost. Therefore, optical methods may still have
significant advantages in breast cancer detection using
such extrinsic contrast agents.
Imaging molecular activity and gene expression
A new advance that holds great promise for breast
cancer research is the recent development of optical
probes for molecular imaging, specifically in the NIR
range. Fluorescent dyes that target specific tumor recep-
tors [12], or that are activated (fluoresce) by tumor-asso-
ciated enzymes (such as cathepsins and matrix
metalloproteinases) [13], have been shown to identify
their molecular targets in vivo. The latter probes probably
hold the greatest promise, because they are quenched in
the absence of the targeted enzymatic activity, yielding
highly specific fluorescence signals.
Fig. 4 depicts the light image and the contrast-enhanced
fluorescence image of a LX-1 tumor implanted into the
mammary fat pad of a nude mouse. The contrast agent
used was a synthetic graft copolymer with Cy5.5-
quenched fluorochromes, which becomes activated in the
presence of cathepsin D. This NIR fluorescent probe
demonstrated a 12-fold signal increase in cancers.
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Figure 2
DOT of ICG enhancement obtained simultaneously with gadolinium-
enhanced MRI of the same breast affected by an 8-mm ductal
carcinoma. (a) Sagittal magnetic resonance image of the breast (in
grayscale) superimposed with the gadolinium enhancement (in color).
The cancerous lesion appears enhanced in the center of the image
because of gadolinium administration. (b) Coronal DOT image of the
absorption coefficient change due to ICG distribution. This image is
perpendicular to the plane of the MRI image in (a) and is obtained for
the volume of interest indicated on (a) with the dashed line box. (c)
Functional magnetic resonance coronal reslicing of the volume of
interest with the same dimensions as (b). Gadolinium enhancement is
averaged over the volume of interest and appears in color. The cancer
appears in the right upper corner of the coronal image and has high
spatial congruence with its appearance on the DOT image. A
secondary lesion on the left, middle part of the image also coregisters
well with the DOT image. A third lesion, which appears on the lower
boundary of the DOT image, is probably an artifact. Although single
slices through the breast volume are shown here, both MRI and DOT
retrieve three-dimensional information of the volume of investigation.
Published with permission from Ntziachristos et al [7]; © 2000
National Academy of Sciences, USA.
Figure 3
DOT of intrinsic breast contrast at 754 nm. The figures display the
distribution of (a) the absorption and (b) reduced scattering coefficient
from a patient with a well-localized 3.4-cm fibroadenoma in the upper
central region of her breast. The geometry is a single plane transecting
the location of the abnormality, in a craniocaudal view. The lesion
appears to have higher absorption than the average background breast
absorption, possibly due to increased vascularization. No significant
scattering contrast is obtained. Spectral information, namely the
combination of such images at multiple wavelengths, can quantify the
vascularization and oxygenation level of breast lesions. From Pogue et
al [27], with permission of the Radiological Society of North America.Using this technology, appropriately engineered fluores-
cent probes can be selectively activated by endogenous
or transferred gene expression. The combination of
such probes with optical imaging may yield a unique,
highly sensitive technology for in vivo and real-time
imaging of the expression patterns for various enzymes,
which are crucially involved in tumor formation and
metastasis. Various breast cancer cell lines have been
identified to over-express specific enzymes such as
matrix metalloproteinases [29], which are not over-
expressed in normal cells.
Therefore, the impact of developing molecular–optical
imaging, and in particular molecular–DOT, of the breast
is potentially enormous. First, selected molecular activity
can be achieved with high sensitivity, because back-
ground fluorescence is quenched. Second, cancers
could be detected at their molecular onset, before
anatomic changes become apparent. Therefore, thera-
pies can be initiated at a very early stage, which is the
single most important strategy in achieving high survival
rates. Third, specific cancer parameters such as growth
kinetics, angiogenesis growth factors, tumor cell
markers, and genetic alterations could be studied
without perturbing the tumor environment. Finally, this
additional information could aid in the development of
novel targeted drugs and therapies, and could allow
assessment of their efficacy at the molecular level. The
importance of this imaging strategy is further amplified
by considering that photon technology can detect single
photons, so that it can resolve fluorescent molecules at
nanomolar to picomolar concentrations, and requires
instrumentation that is of relatively low cost and that
uses nonionizing radiation.
Multimodality imaging
Another exciting application of optical technology is the
combination of optical imagers with other imaging
modalities. Light guidance using optical fibers makes
optical imaging compatible with many other radiologic
methods [24], such as mammography, ultrasound, MRI,
and positron emission tomography, among others. The
development of hybrid modalities offers the potential of
simultaneously scanning the breast, under identical
physiologic and geometric conditions. The optical
method offers several complementary features to those
of established medical imaging methods, mainly through
targeting oxyhemoglobin and deoxyhemoglobin, but also
through the study of molecular events and gene expres-
sion, as discussed above. This can produce an
increased number of features that may augment the
diagnostic value of any single technique alone. Addition-
ally, high-resolution information taken from another
imaging modality can be implemented into the DOT
inversion scheme to improve the quantification accuracy
of the optical method.
Conclusion
Imaging of function and molecular activity is at the frontier
of current research efforts to detect and study cancer non-
invasively. Optical imaging offers complementary features
to those of established radiologic imaging techniques, pri-
marily the quantitative imaging of hemoglobin saturation
and concentration, and the selective imaging of specific
gene expression with high sensitivity, because back-
ground signals can be suppressed using enzyme-acti-
vated fluorescence probes. Similarly to other
technologies, the method can also characterize vascular-
ization, permeability, and a plethora of contrast agents
with high sensitivity, without using harmful radiation and
probably at lesser cost.
Current trends in optical imaging focus on the construc-
tion imagers that yield an increased data-set of optical
measurements per examination, so that higher resolution
and quantification accuracy is achieved. The use of multi-
ple wavelengths in order to capitalize on spectral informa-
tion and to allow the quantification of other tissue
chromophores apart from oxyhemoglobin and deoxyhemo-
globin is also being pursued. More accurate and more effi-
cient forward and inversion problems for improving the
quantification accuracy and reconstruction speed are also
Available online http://breast-cancer-research.com/content/3/1/046
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Figure 4
Imaging molecular function. (a) Light (baseline) image and (b) the
contrast-enhanced fluorescence image of an LX-1 tumor implanted
into the mammary fat pad of a nude mouse, as indicated by the white
arrow. Significant contrast appears between cancer and background
on the fluorescence image. The contrast agent used was a synthetic
graft copolymer with Cy5.5-quenched fluorochromes, which was
activated in the presence of cathepsin D. (c) Dissected tumor in the
mammary pad and (d) histology. Published with permission from
Weissleder et al [13].being investigated. Finally, the abilities of various contrast
agents and probes to assess different functional and mol-
ecular cancer characteristics are being explored. We
believe that optical imaging will play a vital role in our
further understanding of carcinogenesis, in early detection
of cancer, and in the design of effective treatments.
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